Ambrx

United States
San Diego, California, United States, 92037

Company profile

Ambrx company profile

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.

Business identity

Contact email
[email protected]
Phone number
(858)875-2479
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$1M-$10M
Founded
2003-01-01, Year

Headquarters

Postal code
92037
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
9
Total equity funding
$500.9M
Last funding
Post IPO Equity / $75M / 2023-05-24
Last equity funding
Post IPO Equity / $75M
Investors
23
Lead investors
3
Founders
2
Articles
120
Exited on
2021-06-18

Founders and investors

Founders

Peter SchultzTroy Wilson

Lead investors

Apposite CapitalApricot CapitalNortheast Securities

Investors

5AM VenturesBlackRockCormorant Asset ManagementFidelityMaverick Ventures